Altimmune Inc (NASDAQ:ALT) shares are trading higher Monday after the company announced data from the 48-week Phase 2 MOMENTUM clinical trial of pemvidutide. What Happened: Altimmune said it presented ...
GAITHERSBURG, Md., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and metabolic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback